<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00479713</url>
  </required_header>
  <id_info>
    <org_study_id>0653A-809</org_study_id>
    <secondary_id>2007_552</secondary_id>
    <nct_id>NCT00479713</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Cholesterol Lowering Effect of an Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Patients With High Cholesterol and With High Cardiovascular Risk (0653A-809)(COMPLETED)</brief_title>
  <official_title>A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Assess the LDL-C Lowering of Switching to a Combo Tab Ezetimibe/Simvastatin (10 mg/20 mg) Compared to Rosuvastatin 10 mg in Patients With Primary High Cholesterol and High Cardiovascular Risk Not Controlled With a Prior Statin Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      This is a multicenter study to evaluate the safety and efficacy of ezetimibe/simvastatin
      versus rosuvastatin in participants with high cholesterol.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2007</start_date>
  <completion_date type="Actual">March 1, 2008</completion_date>
  <primary_completion_date type="Actual">March 1, 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in Low Density Lipoprotein-Cholesterol (LDL-C) at Study Endpoint After Six Weeks of Treatment</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>Percent Change in LDL-C at study endpoint after six weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure *100.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Participants Achieving Designated Low Density Lipoprotein-Cholesterol (LDL-C) Levels After 6 Weeks of Treatment</measure>
    <time_frame>after 6 weeks of treatment</time_frame>
    <description>The percentage of participants who achieved a target LDL-C goal of &lt; 100 mg/dL, of &lt;70 mg/dL, and of &lt;77 mg/dL at study endpoint after six weeks of treatment.
The numerator is the number of participants in a treatment group who achieved a target LDL-C goal and the denominator is the total number of participants within that treatment group.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Percent Change From Baseline in Total Cholesterol</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>Percent change from baseline in total cholesterol at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure *100.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change From Baseline in Triglycerides.</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>Percent change from baseline in triglycerides at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure *100.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C)</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>Percent change from baseline in HDL-C at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure *100.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change From Baseline in Non-High Density Lipoprotein-Cholesterol (Non-HDL-C)</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>Percent change from baseline in non HDL-C at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure *100.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C)/High Density Lipoprotein-Cholesterol (HDL-C) Ratio</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>Percent change from baseline in LDL-C/HDL-C ratio at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure *100.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change From Baseline in Total Cholesterol/High Density Lipoprotein-Cholesterol (HDL-C) Ratio</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>Percent change from baseline in total cholesterol/HDL-C ratio at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure *100.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change From Baseline in Apolipoprotein B</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>Percent change from baseline in apolipoprotein (Apo) B at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure *100.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change From Baseline in High-sensitivity C (Hs-C) Reactive Protein</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>Percent change from baseline in hs-C reactive protein at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure *100.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">618</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 1: drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 2: active comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ezetimibe (+) simvastatin</intervention_name>
    <description>ezetimibe/simvastatin 10/20mg. The treatment duration will be 6 weeks.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>MK0653A</other_name>
    <other_name>Vytorin®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator : rosuvastatin calcium</intervention_name>
    <description>rosuvastatin 10mg. The treatment duration will be 6 weeks.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Placebo (unspecified)</intervention_name>
    <description>rosuvastatin 10mg Placebo. The treatment duration will be 6 weeks.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Placebo (unspecified)</intervention_name>
    <description>ezetimibe/simvastatin 10/20mg Placebo. The treatment duration will be 6 weeks.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant is currently taking a statin medication for the treatment of high
             cholesterol

          -  Participant has an LDL-C level that is greater than or equal to 100 mg/dl and less
             than or equal to 190 mg/dl

        Exclusion Criteria:

          -  Women who are pregnant or nursing, or women who intend to become pregnant

          -  Participant has any condition, situation, or is currently taking any medication that
             might pose a risk to the participant or interfere with participation in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Netherlands</country>
    <country>Portugal</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>(MedWatch - FDA maintained medical product safety Information)</description>
  </link>
  <link>
    <url>http://www.merck.com/product/patients_caregivers/home.html</url>
    <description>(Merck: Patient &amp; Caregiver U.S. Product Web Site)</description>
  </link>
  <reference>
    <citation>Farnier M, Averna M, Missault L, Vaverkova H, Viigimaa M, Massaad R, Vandormael K, Johnson-Levonas AO, Brudi P. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study. Int J Clin Pract. 2009 Apr;63(4):547-59. doi: 10.1111/j.1742-1241.2009.02022.x. Epub 2009 Feb 16.</citation>
    <PMID>19222610</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2007</study_first_submitted>
  <study_first_submitted_qc>May 24, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2007</study_first_posted>
  <results_first_submitted>February 11, 2009</results_first_submitted>
  <results_first_submitted_qc>April 16, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 10, 2009</results_first_posted>
  <last_update_submitted>March 31, 2017</last_update_submitted>
  <last_update_submitted_qc>March 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>High Cholesterol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
    <mesh_term>Ezetimibe, Simvastatin Drug Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Phase IV
First Participant In: 31-Mar-2007; Last Participant Last Visit 11-Mar-2008
85 centers worldwide (EX US)
Eligible participants include those on a stable dose of one of the following: rosuvastatin 5 mg; simvastatin 20 mg, 40 mg; atorvastatin 10, 20 mg; pravastatin 40 mg; fluvastatin 80 mg.</recruitment_details>
      <pre_assignment_details>Eligible participants were randomized at Visit 2 (Week 6) to either a combination tablet of ezetimibe/simvastatin (10 mg/20 mg) plus a matching placebo for rosuvastatin 10 mg (Group 1) or rosuvastatin 10 mg plus a matching placebo for the combination tablet (Group 2) for a 6-week treatment period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ezetemibe + Simvastatin</title>
          <description>Ezetemibe 10 mg + Simvastatin 20 mg plus a matching placebo for rosuvastatin 10 mg QD (once a day) for 6 weeks</description>
        </group>
        <group group_id="P2">
          <title>Rosuvastatin</title>
          <description>Rosuvastatin 10 mg plus a matching placebo for the combination tablet QD (once a day) for 6 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="314"/>
                <participants group_id="P2" count="304"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="301"/>
                <participants group_id="P2" count="295"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ezetemibe + Simvastatin</title>
          <description>Ezetemibe 10 mg + Simvastatin 20 mg plus a matching placebo for rosuvastatin 10 mg QD (once a day) for 6 weeks</description>
        </group>
        <group group_id="B2">
          <title>Rosuvastatin</title>
          <description>Rosuvastatin 10 mg plus a matching placebo for the combination tablet QD (once a day) for 6 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="314"/>
            <count group_id="B2" value="304"/>
            <count group_id="B3" value="618"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.2" lower_limit="38" upper_limit="82"/>
                    <measurement group_id="B2" value="63.1" lower_limit="27" upper_limit="80"/>
                    <measurement group_id="B3" value="63.15" lower_limit="27" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="129"/>
                    <measurement group_id="B2" value="119"/>
                    <measurement group_id="B3" value="248"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="185"/>
                    <measurement group_id="B2" value="185"/>
                    <measurement group_id="B3" value="370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="314"/>
                    <measurement group_id="B2" value="302"/>
                    <measurement group_id="B3" value="616"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="277"/>
                    <measurement group_id="B2" value="261"/>
                    <measurement group_id="B3" value="538"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Apolipoprotein B</title>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.20" spread="0.20"/>
                    <measurement group_id="B2" value="1.18" spread="0.21"/>
                    <measurement group_id="B3" value="1.19" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>C Reactive Protein</title>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.16" spread="0.26"/>
                    <measurement group_id="B2" value="0.15" spread="0.26"/>
                    <measurement group_id="B3" value="0.16" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>High Density Lipoprotein-Cholesterol</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.43" spread="0.37"/>
                    <measurement group_id="B2" value="1.43" spread="0.36"/>
                    <measurement group_id="B3" value="1.43" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Low Density Lipoprotein-Cholesterol (LDL-C)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.21" spread="0.42"/>
                    <measurement group_id="B2" value="3.24" spread="0.44"/>
                    <measurement group_id="B3" value="3.23" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Low Density Lipoprotein-Cholesterol (LDL-C):High Density Lipoprotein-Cholesterol (HDL-C) ratio</title>
          <units>LDL-C:HDL-C ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.38" spread="0.65"/>
                    <measurement group_id="B2" value="2.40" spread="0.65"/>
                    <measurement group_id="B3" value="2.39" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Non-High Density Lipoprotein-Cholesterol (Non-HDL-C)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.95" spread="0.55"/>
                    <measurement group_id="B2" value="3.95" spread="0.56"/>
                    <measurement group_id="B3" value="3.95" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Cholesterol</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.38" spread="0.57"/>
                    <measurement group_id="B2" value="5.38" spread="0.61"/>
                    <measurement group_id="B3" value="5.38" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total cholesterol:High Density Lipoprotein-Cholesterol (HDL-C) ratio</title>
          <units>Total cholesterol:HDL-C ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.94" spread="0.89"/>
                    <measurement group_id="B2" value="3.96" spread="0.90"/>
                    <measurement group_id="B3" value="3.95" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Triglycerides</title>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.46" spread="0.86"/>
                    <measurement group_id="B2" value="1.41" spread="0.87"/>
                    <measurement group_id="B3" value="1.42" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Low Density Lipoprotein-Cholesterol (LDL-C) at Study Endpoint After Six Weeks of Treatment</title>
        <description>Percent Change in LDL-C at study endpoint after six weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure *100.</description>
        <time_frame>Baseline and 6 weeks</time_frame>
        <population>Full Analysis Set (FAS): The FAS population includes all randomized participants who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetemibe + Simvastatin</title>
            <description>Ezetemibe 10 mg + Simvastatin 20 mg plus a matching placebo for rosuvastatin 10 mg QD (once a day) for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin 10 mg plus a matching placebo for the combination tablet QD (once a day) for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Low Density Lipoprotein-Cholesterol (LDL-C) at Study Endpoint After Six Weeks of Treatment</title>
          <description>Percent Change in LDL-C at study endpoint after six weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure *100.</description>
          <population>Full Analysis Set (FAS): The FAS population includes all randomized participants who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value.</population>
          <units>percent change from baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="297"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.66" lower_limit="-30.27" upper_limit="-25.04"/>
                    <measurement group_id="O2" value="-16.94" lower_limit="-19.61" upper_limit="-14.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;=0.001</p_value>
            <method>ANOVA</method>
            <method_desc>Model terms: treatment, stratum, baseline (categorized based on quartiles) and center</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-10.72</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.72</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-14.10</ci_lower_limit>
            <ci_upper_limit>-7.33</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of Participants Achieving Designated Low Density Lipoprotein-Cholesterol (LDL-C) Levels After 6 Weeks of Treatment</title>
        <description>The percentage of participants who achieved a target LDL-C goal of &lt; 100 mg/dL, of &lt;70 mg/dL, and of &lt;77 mg/dL at study endpoint after six weeks of treatment.
The numerator is the number of participants in a treatment group who achieved a target LDL-C goal and the denominator is the total number of participants within that treatment group.</description>
        <time_frame>after 6 weeks of treatment</time_frame>
        <population>Full Analysis Set (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetemibe + Simvastatin</title>
            <description>Ezetemibe 10 mg + Simvastatin 20 mg plus a matching placebo for rosuvastatin 10 mg QD (once a day) for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin 10 mg plus a matching placebo for the combination tablet QD (once a day) for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Participants Achieving Designated Low Density Lipoprotein-Cholesterol (LDL-C) Levels After 6 Weeks of Treatment</title>
          <description>The percentage of participants who achieved a target LDL-C goal of &lt; 100 mg/dL, of &lt;70 mg/dL, and of &lt;77 mg/dL at study endpoint after six weeks of treatment.
The numerator is the number of participants in a treatment group who achieved a target LDL-C goal and the denominator is the total number of participants within that treatment group.</description>
          <population>Full Analysis Set (FAS)</population>
          <units>Percent of participant population</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="297"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LDL-C &lt;100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.46"/>
                    <measurement group_id="O2" value="56.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL-C &lt;70</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.25"/>
                    <measurement group_id="O2" value="11.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percentage of Participants who Attained Target LDL-C Goal of &lt; 100 mg/dL (2.59 mmol/L)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;=0.001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Model terms: treatment, stratum and baseline LDL-C (continuous)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.5</ci_lower_limit>
            <ci_upper_limit>3.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percentage of Participants who Attained Target LDL-C Goal of &lt; 70 mg/dL (1.81 mmol/L)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;=0.001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Model terms: treatment, stratum and baseline LDL-C (continuous)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.8</ci_lower_limit>
            <ci_upper_limit>4.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change From Baseline in Total Cholesterol</title>
        <description>Percent change from baseline in total cholesterol at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure *100.</description>
        <time_frame>Baseline and 6 weeks</time_frame>
        <population>Full Analysis Set (FAS): The FAS population includes all randomized participants who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetemibe + Simvastatin</title>
            <description>Ezetemibe 10 mg + Simvastatin 20 mg plus a matching placebo for rosuvastatin 10 mg QD (once a day) for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin 10 mg plus a matching placebo for the combination tablet QD (once a day) for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Cholesterol</title>
          <description>Percent change from baseline in total cholesterol at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure *100.</description>
          <population>Full Analysis Set (FAS): The FAS population includes all randomized participants who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value.</population>
          <units>percent change from baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="297"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.53" lower_limit="-19.36" upper_limit="-15.71"/>
                    <measurement group_id="O2" value="-10.33" lower_limit="-12.19" upper_limit="-8.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;=0.001</p_value>
            <method>ANOVA</method>
            <method_desc>Model terms: treatment, stratum, baseline (categorized based on quartiles) and center</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-7.20</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.20</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-9.56</ci_lower_limit>
            <ci_upper_limit>-4.84</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change From Baseline in Triglycerides.</title>
        <description>Percent change from baseline in triglycerides at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure *100.</description>
        <time_frame>Baseline and 6 weeks</time_frame>
        <population>Full Analysis Set (FAS): The FAS population includes all randomized participants who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetemibe + Simvastatin</title>
            <description>Ezetemibe 10 mg + Simvastatin 20 mg plus a matching placebo for rosuvastatin 10 mg QD (once a day) for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin 10 mg plus a matching placebo for the combination tablet QD (once a day) for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Triglycerides.</title>
          <description>Percent change from baseline in triglycerides at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure *100.</description>
          <population>Full Analysis Set (FAS): The FAS population includes all randomized participants who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value.</population>
          <units>percent change from baseline</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="297"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.00" lower_limit="-15.25" upper_limit="-6.80"/>
                    <measurement group_id="O2" value="-5.26" lower_limit="-9.92" upper_limit="-1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.056</p_value>
            <method>Nonparametric ANOVA</method>
            <method_desc>ANOVA model based on Tukey’s normalized ranks with term for treatment, stratum, baseline (categorized based on quartiles) and center.</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-5.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-9.56</ci_lower_limit>
            <ci_upper_limit>-0.30</ci_upper_limit>
            <estimate_desc>The median difference between treatments is based on the Hodges-Lehmann estimates of shift with a corresponding distribution-free Confidence Interval (CI) based on Wilcoxon’s rank.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C)</title>
        <description>Percent change from baseline in HDL-C at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure *100.</description>
        <time_frame>Baseline and 6 weeks</time_frame>
        <population>Full Analysis Set (FAS): The FAS population includes all randomized participants who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetemibe + Simvastatin</title>
            <description>Ezetemibe 10 mg + Simvastatin 20 mg plus a matching placebo for rosuvastatin 10 mg QD (once a day) for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin 10 mg plus a matching placebo for the combination tablet QD (once a day) for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C)</title>
          <description>Percent change from baseline in HDL-C at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure *100.</description>
          <population>Full Analysis Set (FAS): The FAS population includes all randomized participants who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value.</population>
          <units>percent change from baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="297"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.12" lower_limit="0.34" upper_limit="3.89"/>
                    <measurement group_id="O2" value="3.03" lower_limit="1.22" upper_limit="4.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.433</p_value>
            <method>ANOVA</method>
            <method_desc>Model terms: treatment, stratum, baseline (categorized based on quartiles) and center.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.92</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.17</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.21</ci_lower_limit>
            <ci_upper_limit>1.38</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change From Baseline in Non-High Density Lipoprotein-Cholesterol (Non-HDL-C)</title>
        <description>Percent change from baseline in non HDL-C at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure *100.</description>
        <time_frame>Baseline and 6 weeks</time_frame>
        <population>Full Analysis Set (FAS): The FAS population includes all randomized participants who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetemibe + Simvastatin</title>
            <description>Ezetemibe 10 mg + Simvastatin 20 mg plus a matching placebo for rosuvastatin 10 mg QD (once a day) for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin 10 mg plus a matching placebo for the combination tablet QD (once a day) for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Non-High Density Lipoprotein-Cholesterol (Non-HDL-C)</title>
          <description>Percent change from baseline in non HDL-C at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure *100.</description>
          <population>Full Analysis Set (FAS): The FAS population includes all randomized participants who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value.</population>
          <units>percent change from baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="297"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.42" lower_limit="-25.81" upper_limit="21.03"/>
                    <measurement group_id="O2" value="-14.01" lower_limit="-16.46" upper_limit="-11.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;=0.001</p_value>
            <method>ANOVA</method>
            <method_desc>Model terms: treatment, stratum, baseline (categorized based on quartiles) and center.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-9.41</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.58</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-12.50</ci_lower_limit>
            <ci_upper_limit>-6.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C)/High Density Lipoprotein-Cholesterol (HDL-C) Ratio</title>
        <description>Percent change from baseline in LDL-C/HDL-C ratio at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure *100.</description>
        <time_frame>Baseline and 6 weeks</time_frame>
        <population>Full Analysis Set (FAS): The FAS population includes all randomized participants who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetemibe + Simvastatin</title>
            <description>Ezetemibe 10 mg + Simvastatin 20 mg plus a matching placebo for rosuvastatin 10 mg QD (once a day) for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin 10 mg plus a matching placebo for the combination tablet QD (once a day) for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C)/High Density Lipoprotein-Cholesterol (HDL-C) Ratio</title>
          <description>Percent change from baseline in LDL-C/HDL-C ratio at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure *100.</description>
          <population>Full Analysis Set (FAS): The FAS population includes all randomized participants who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value.</population>
          <units>percent change from baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="297"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.41" lower_limit="-30.42" upper_limit="-24.40"/>
                    <measurement group_id="O2" value="-17.82" lower_limit="-20.89" upper_limit="-14.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;=0.001</p_value>
            <method>ANOVA</method>
            <method_desc>Model terms: treatment, stratum, baseline (categorized based on quartiles) and center.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-9.59</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.98</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-13.49</ci_lower_limit>
            <ci_upper_limit>-5.69</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change From Baseline in Total Cholesterol/High Density Lipoprotein-Cholesterol (HDL-C) Ratio</title>
        <description>Percent change from baseline in total cholesterol/HDL-C ratio at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure *100.</description>
        <time_frame>Baseline and 6 weeks</time_frame>
        <population>Full Analysis Set (FAS): The FAS population includes all randomized participants who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetemibe + Simvastatin</title>
            <description>Ezetemibe 10 mg + Simvastatin 20 mg plus a matching placebo for rosuvastatin 10 mg QD (once a day) for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin 10 mg plus a matching placebo for the combination tablet QD (once a day) for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Cholesterol/High Density Lipoprotein-Cholesterol (HDL-C) Ratio</title>
          <description>Percent change from baseline in total cholesterol/HDL-C ratio at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure *100.</description>
          <population>Full Analysis Set (FAS): The FAS population includes all randomized participants who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value.</population>
          <units>percent change from baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="297"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.76" lower_limit="-19.94" upper_limit="-15.57"/>
                    <measurement group_id="O2" value="-11.51" lower_limit="-13.74" upper_limit="-9.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;=0.001</p_value>
            <method>ANOVA</method>
            <method_desc>Model terms: treatment, stratum, baseline (categorized based on quartiles) and center.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-6.25</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.44</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-9.07</ci_lower_limit>
            <ci_upper_limit>-3.43</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change From Baseline in Apolipoprotein B</title>
        <description>Percent change from baseline in apolipoprotein (Apo) B at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure *100.</description>
        <time_frame>Baseline and 6 weeks</time_frame>
        <population>Full Analysis Set (FAS): The FAS population includes all randomized participants who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetemibe + Simvastatin</title>
            <description>Ezetemibe 10 mg + Simvastatin 20 mg plus a matching placebo for rosuvastatin 10 mg QD (once a day) for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin 10 mg plus a matching placebo for the combination tablet QD (once a day) for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Apolipoprotein B</title>
          <description>Percent change from baseline in apolipoprotein (Apo) B at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure *100.</description>
          <population>Full Analysis Set (FAS): The FAS population includes all randomized participants who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value.</population>
          <units>percent change from baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="301"/>
                <count group_id="O2" value="292"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.87" lower_limit="-20.05" upper_limit="-15.70"/>
                    <measurement group_id="O2" value="-9.77" lower_limit="-11.99" upper_limit="-7.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;=0.001</p_value>
            <method>ANOVA</method>
            <method_desc>Model terms: treatment, stratum, baseline (categorized based on quartiles) and center</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-8.11</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.43</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-10.91</ci_lower_limit>
            <ci_upper_limit>-5.30</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change From Baseline in High-sensitivity C (Hs-C) Reactive Protein</title>
        <description>Percent change from baseline in hs-C reactive protein at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure *100.</description>
        <time_frame>Baseline and 6 weeks</time_frame>
        <population>Full Analysis Set (FAS): The FAS population includes all randomized participants who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetemibe + Simvastatin</title>
            <description>Ezetemibe 10 mg + Simvastatin 20 mg plus a matching placebo for rosuvastatin 10 mg QD (once a day) for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin 10 mg plus a matching placebo for the combination tablet QD (once a day) for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in High-sensitivity C (Hs-C) Reactive Protein</title>
          <description>Percent change from baseline in hs-C reactive protein at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure *100.</description>
          <population>Full Analysis Set (FAS): The FAS population includes all randomized participants who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value.</population>
          <units>percent change from baseline</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="301"/>
                <count group_id="O2" value="293"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.33" lower_limit="-16.67" upper_limit="0.00"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-7.14" upper_limit="6.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.172</p_value>
            <method>Nonparametric ANOVA</method>
            <method_desc>ANOVA model based on Tukey’s normalized ranks with term for treatment, stratum, baseline (categorized based on quartiles) and center</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-6.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-16.67</ci_lower_limit>
            <ci_upper_limit>2.87</ci_upper_limit>
            <estimate_desc>The median difference between treatments is based on the Hodges-Lehmann estimates of shift with a corresponding distribution-free CI based on Wilcoxon’s rank</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Adverse event tables include all participants who took at least one dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ezetemibe + Simvastatin</title>
          <description>Ezetemibe 10 mg + Simvastatin 20 mg plus a matching placebo for rosuvastatin 10 mg QD (once a day) for 6 weeks</description>
        </group>
        <group group_id="E2">
          <title>Rosuvastatin</title>
          <description>Rosuvastatin 10 mg plus a matching placebo for the combination tablet QD (once a day) for 6 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3"/>
                <counts group_id="E2" subjects_affected="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>In-stent arterial restenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Subarachnoid hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Epileptic seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin eruption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19"/>
                <counts group_id="E2" subjects_affected="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Salivary hypersecretion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Vomitting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Deafness traumatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Sensation of heaviness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Syncope vasovagal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Throat tightness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vice President, Late Stage Development Group Leader</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

